Collegium Pharmaceutical Inc
Research Collegium Pharmaceutical Inc (COLL) on Bullrun: valuation model: 6.7% undervalued, market cap USD 892.73M, P/E 22.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCOLL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Valuation signal6.7% undervalued
- Market capUSD 892.73M
- P/E22.3
- Financial periodQ2 2026
- RevenueUSD 199.88M
- Net income-USD 15.05M
- Free cash flowUSD 70.83M
- Gross margin55.2%
Valuation Snapshot
Bullrun's latest valuation model marks Collegium Pharmaceutical Inc as 6.7% undervalued; latest market cap is USD 892.73M; P/E is 22.3.
Peer valuation comparison
Latest P/E is 22.25x versus a Healthcare sector median of 24.46x (9.0% below).
Latest P/E is 22.25x versus a United States median of 24.87x (10.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 780.57M | USD 63.00M | USD 327.58M | 59.3% | 1.73 | USD 231.25M | USD 814.86M | USD 301.68M |
| FY2024 | USD 631.45M | USD 69.00M | USD 203.33M | 59.8% | 1.86 | USD 70.57M | USD 859.30M | USD 228.84M |
| FY2023 | USD 566.77M | USD 48.00M | USD 274.29M | 57.5% | 1.29 | USD 238.95M | USD 674.28M | USD 195.43M |
| FY2022 | USD 463.93M | -USD 25.00M | USD 122.61M | 45.2% | -0.74 | USD 173.69M | USD 754.91M | USD 194.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 892.73M | 22.3 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.47B | 26.9 | n/a | n/a |
| 2024 | 2024-12-31 | USD 900.76M | 15.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.00B | 205.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 778.87M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 628.68M | 11.3 | n/a | n/a |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Collegium Pharmaceutical Inc overvalued or undervalued?
Bullrun's valuation model currently marks Collegium Pharmaceutical Inc as 6.7% undervalued.
What is Collegium Pharmaceutical Inc's market cap?
Collegium Pharmaceutical Inc's market capitalization is USD 892.73M.
What is Collegium Pharmaceutical Inc's P/E ratio?
Collegium Pharmaceutical Inc's price-to-earnings (P/E) ratio is 22.3.
What does Collegium Pharmaceutical Inc do?
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.